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Over the past 8 years several lines of compelling evidence have indicated 
that microRNAs are critical downstream 
effectors of classic oncogene/tumor sup-
pressor networks. The archetypal exam-
ples of oncogene and tumor suppressor 
microRNAs are the miR-17-92 (oncomir 1) 
polycistron and miR-34 respectively. 
Whilst the involvement of these two 
opposing families of microRNAs in 
oncogenesis has been known for some 
time, the mRNA targets through which 
they exert their phenotypes are only just 
beginning to be uncovered. Moreover, 
several recent reports have demonstrated 
that the relevant physiological targets of 
certain individual microRNAs are actu-
ally fairly limited, with repression of just 
one or two major targets sufficient to 
explain the observed phenotype. In this 
review we will discuss the emerging role 
of microRNAs in tumorigenesis with 
a specific focus on miR-34c-dependent 
regulation of Myc.
Do MicroRNAs Act  
through the Many or the Few?
MicroRNAs are non-coding RNA mol-
ecules 18–24 nucleotides in length that 
regulate gene expression. They gener-
ally function by binding with imper-
fect Watson-Crick base pairing to target 
sequences within the 3' UTR of protein 
coding mRNAs leading to their trans-
lational repression.1 There are over 700 
identified microRNAs in the human 
genome which are, themselves, subject to 
regulation at the transcriptional and post-
transcriptional levels. MicroRNAs are 
generally transcribed by RNA Polymerase 
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II (Pol II) and are regulated by transcrip-
tion factors, transcriptional co-activators 
and chromatin modifications much like 
any protein coding Pol II transcript. 
Once produced the primary microRNA 
(pri-miR) transcript is spliced and/or pro-
cessed by the enzyme Drosha to form a 
precursor microRNA (pre-miR) which 
is exported from the nucleus and further 
processed by the RNAse III enzyme Dicer 
to form the mature microRNA duplex.2 
One strand of this duplex is loaded into 
one of the Argonaute protein family 
members (AGO1-4 in mammals) which 
recruits other factors such as GW182 
(TNRC6A-C) to form a microRNA-
induced silencing complex (miRISC). 
MiRISC is recruited to the 3' UTR1 of 
mRNA targets by virtue of microRNA-
mRNA base pairing, thus eliciting 
translational repression and/or mRNA 
destabilisation. The magnitude of transla-
tional repression appears to differ between 
microRNA-mRNA pairs for reasons that 
remain unknown, although there is evi-
dence that sequence specific RNA bind-
ing proteins have a role to play.3 Indeed, 
the precise mechanism by which microR-
NAs repress the translation of their target 
mRNAs is a matter of debate with many 
factors being implicated in this process.1
Each individual microRNA in the 
genome is predicted to regulate, on aver-
age, upwards of 200 protein coding 
mRNAs by binding to target sites within 
the 3' UTR. However, identifying the 
mRNAs that are true physiological targets 
of a given microRNA is a major challenge 
within the field. It has been proposed that 
microRNAs exert their function by acting 
as rheostats to fine-tune gene expression 
www.landesbioscience.com Cell Cycle 2727
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are numerous reports of alterations in 
miR-34 expression in cancer highlight-
ing the importance of this microRNA 
family in oncogenesis. For example, miR-
34a is deleted in ~30% of neuroblastomas 
and the miR-34b/c promoter region is 
frequently epigentically silenced in met-
astatic cancer cell lines. (For further exam-
ples of miR-34 alterations in cancer see 
Table 1). The different members of the 
miR-34 family target several cell cycle 
regulators although which of these 
mRNAs is/are responsible for their anti-
proliferative affects and whether the three 
members have distinct or overlapping 
targets is only starting to be elucidated. 
Furthermore, the precise role of miR-34 
in the DNA damage response is yet to be 
fully defined.
We have recently shown that Myc 
is negatively regulated by miR-34c in 
response to DNA damage and that this is 
a crucial event in limiting Myc-induced 
DNA synthesis. Inhibition of miR-34c 
following DNA damage prevents S-phase 
arrest and leads to increased DNA synthe-
sis, DNA damage and checkpoint activa-
tion. Remarkably, despite the number of 
predicted (and known) mRNA targets of 
miR-34c all these phenotypes of miR-34c 
inhibition are reversed when miR-34c is 
inhibited in combination with depletion 
of Myc by RNAi.11 These data suggest 
that following DNA damage Myc is a 
major target of miR-34c and have impor-
tant implications for our understanding of 
Myc biology. Continued replication under 
stress conditions may be one mechanism 
by which Myc promotes genomic instabil-
ity and achieves its oncogenic potential.32 
Our data argue that miR-34c lies at the 
centre of a pathway that acts to remove 
Myc in order to prevent this oncogenic 
function (Fig. 2). Whilst Myc is clearly an 
important target of miR-34c we cannot 
rule out the possibility that other miR-34c 
targets are important in different cellular 
contexts. However, several other miR-34c 
targets, both experimentally validated and 
predicted, are also transcriptional targets 
of Myc (www.myc-cancer-gene.org) so 
these targets may be controlled by miR-
34c both directly (by translational repres-
sion via their 3' UTR) and indirectly (by 
a reduction in transcription due a decrease 
in Myc levels). One target of miR-34c that 
cell cycle, primarily through the Myc-
associated zinc finger protein, Miz1.14,15 
In addition to regulating protein coding 
mRNAs, Myc transcriptionally regulates 
a number of non-coding RNA transcripts 
including ribosomal RNAs, tRNAs and 
microRNAs.16 Myc has been a major 
focus of microRNA research for many 
years. It globally represses microRNA 
transcription,17 inhibits the biogenesis of 
the tumor suppressor microRNA let-7 
through Lin-28,18 and specifically acti-
vates certain oncogenic microRNAs 
such as miR-17-92.19,20 MiR-17-92 is a 
polycistronic microRNA cluster consist-
ing of miR-17, 18a, 19a, 20a, 19b and 
92a that is transcriptionally activated by 
Myc,19 co-operates with Myc to accelerate 
B-cell lymphomagenesis20 and augments 
tumor angiogenesis.21 Until recently it 
was unknown whether the oncogenicity 
of miR-17-92 was due to the concerted 
action of all its components or whether it 
could be attributed to a single microRNA. 
Two recent reports demonstrated that 
miR-19 is the principal oncogenic com-
ponent of this cluster in vivo and sug-
gest that the tumor suppressor PTEN is a 
major target of miR-19.22-24 Myc also has 
non-transcriptional functions. It directly 
interacts with components of the repli-
cation machinery to positively regulate 
DNA synthesis. Overexpression of Myc 
in this context causes inappropriate repli-
cation origin firing leading to replication 
stress and genomic instability evidenced 
by the activation of a DNA damage 
response.25 This is particularly important 
since genomic instability is a hallmark 
of cancer26 and is evident in Myc-driven 
tumors in vivo.27 Clearly these pleiotropic 
functions mean Myc must be tightly con-
trolled in order to prevent tumorgenesis, 
although Myc alone cannot transform 
cells and requires at least one co-operating 
oncogene.28
The miR-34 family comprising miR-
34a, 34b and 34c, were first identified as 
direct transcriptional targets of p53.12,29-31 
MiR-34a is the most well characterised 
family member and is transcribed from 
a separate locus to miR-34b/c which are 
produced as a single primary transcript.13 
All three of these microRNAs have potent 
anti-proliferative affects with miR-34a 
additionally promoting apoptosis.13 There 
through modestly (10–20%) repressing a 
large number of mRNAs and this is sup-
ported by large scale proteomic studies.4,5 
However, there is increasing evidence 
that the observed phenotype of certain 
microRNAs that act as master regulators 
of cell fate can be explained by the sub-
stantial repression (50–70%) of a fairly 
limited (2–3) repertoire of important 
mRNA targets. For example, miR-31 
inhibits tumor metastasis, a phenotype 
that can be explained by repression of just 
three targets; RhoA, integrin-alpha5 and 
radixin.6,7 Similarly, the pro-metastatic 
microRNA miR-10b appears to function 
primarily by repressing HOXD10, since 
the phenotype of miR-10b inhibition is 
reversed when HOXD10 is depleted by 
RNAi.8 Using “knock-in” technology 
two groups simultaneously demonstrated 
that expression of an activation induced 
cytidine-deaminase (AID) mRNA with a 
mutant miR-155 target-site in its 3' UTR 
partially phenocopies deletion of miR-155 
in vivo.9,10 Taken together these observa-
tions suggest that certain microRNAs act 
on a subset of critical mRNA targets which 
are necessary and sufficient to explain the 
majority of their effects, although this 
does not rule out the possibility that the 
modest repression of a more substantial 
number of mRNAs contributes to both 
the magnitude and robustness of the phe-
notype. Our recent data suggest that Myc 
is a major physiological target of miR-34c 
in response to DNA damage-inducing 
chemotherapy,11 providing mechanistic 
insight into the anti-proliferative effects of 
this tumor suppressor microRNA.12,13
Myc is a Major Target of miR-34c 
in Response to DNA Damage
The proto-oncogene c-Myc (hereafter 
referred to as Myc) is a master regulator 
of cell proliferation and transformation 
through both transcriptional and non-
transcriptional means and is frequently 
deregulated in human malignancies. 
As a transcription factor Myc binds to 
E-box elements (with its partner Max) 
and activates the transcription of genes 
whose products function to drive cell 
cycle progression and cell growth. Myc 
also negatively regulates the transcrip-
tion of genes which function to arrest the 
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MK2, evolved prior to the p53-dependent 
mechanism. Since p38 MAPK is a gen-
eral  stress-response kinase activated by 
a diverse range of stimuli,40 it is possible 
that the p38 MAPK/MK2 acting through 
miR-34c may control Myc-dependent 
DNA synthesis in response to a variety 
of different stresses. Indeed induction of 
miR-34c and repression of Myc occur in 
response to sodium arsenite treatment 
(Fig. 1), a general p38 MAPK activator.41 
We propose that the p38 MAPK/MK2/
miR-34c pathway functions to prevent 
Myc-dependent DNA replication under 
stress. Loss of this regulatory mechanism 
may facilitate replication under stress and 
promote genomic instability, a potentially 
oncogenic function of Myc32,42,43 (Fig. 2).
Biological Significance  
of miR-34c-Mediated Repression 
of Myc
Members of the miR-34 family are known 
to induce a senescent-like growth arrest 
when overexpressed in cells, with miR-
34c being the most potent.12 We provided 
mechanistic insight into this striking 
effect by showing that miR-34c inhibi-
tion of Myc in response to DNA dam-
age prevents S-phase progression. Thus 
miR-34c through repression of Myc 
cycle arrest thus allowing DNA repair.34 
Cancer cells frequently bypass one or 
more of these checkpoint pathways ren-
dering such cells reliant upon the remain-
ing checkpoints to maintain DNA 
damage below a threshold which induces 
cell death. In particular MK2 appears to 
be essential for S-phase and G
2
/M arrest 
in cells that are devoid of p53, and its 
inhibition specifically sensitises p53-defi-
cient cells to DNA damage-induced cell 
death.36 Therefore it would appear that 
checkpoint kinases and perhaps their 
downstream effectors may be attractive 
therapeutic candidates in specific cellular 
contexts.37 The miR-34 family were first 
identified as direct transcriptional targets 
of p53, although induction of miR-34b/c 
in response to DNA damage11 and miR-
34a in response to B-Raf induced senes-
cence38 still occur in the absence of p53. 
We found that in the absence of p53 the 
p38 MAPK pathway, through MK2, con-
trols miR-34b/c induction in response 
to DNA damage11 raising the possibil-
ity that miR-34c may function as part of 
the MK2-mediated S-phase checkpoint. 
Indeed miR-34 induction in response 
to DNA damage in C. elegans is identi-
cal in wild-type and cep1/p53 mutant 
strains39 suggesting that another mecha-
nism, perhaps involving p38 MAPK/
cannot be ignored is Bcl-2, whilst neither 
Myc nor Bcl-2 on their own can convert 
cells to a tumorigenic state, together these 
potent oncogenes can co-operate to trans-
form cells.28,33 The question of whether 
genetic loss of miR-34c alone leads to 
tumorgenesis in vivo, however, awaits the 
miR-34c “knock-out” mouse.
Pathways Upstream  
of miR-34c-Myc
Double-strand breaks to DNA caused by 
ionizing radiation or chemotherapeutic 
drugs initiate a DNA damage response.34 
The DDR links the recognition of DNA 
damage sites to cell cycle arrest (to allow 
DNA repair) or apoptosis (to eliminate 
the damaged cell) through a series of 
kinase signalling networks.35 Double-
strand breaks are recognized by the MRN 
complex (consisting of Mre11, Rad50 and 
Nbs1) which, in conjunction with phos-
phorylated H2AX, amplifies the DNA 
damage signal. This in turn leads to local 
activation of the phosphotidyl inositol-3 
kinase like (PI3K) family members ATM/
ATR, which transduce the signal to the 
downstream checkpoint kinases CHK1, 
CHK2 and p38 MAPK/MAPKAPK2. 
These checkpoint kinases, through phos-
phorylation of their substrates, initiate cell 
Table 1. the mir-34 family in human cancer
Cancer type Family member
Up/downregulation 
 (compared to normal tissue)
% of primary tumors  
(if known)
Biological function Ref
Colorectal cancer mir-34b, mir-34c Down, Hyper-methylated 90%
inhibition of cell 
growth
51
High grade serous 
ovarian carcinomas
mir-34c Down, Unkown mechanism Unknown
Low expression 
 correlates with poor 
survival
52
Osteosarcoma
mir-34a, mir-34b, 
mir-34c
Down, Small degree of loss of 
heterzygosity, small degree 
of methylation
~20%
increase in G1, 
 promotes apoptosis
53
Colon, melanoma, 
head and neck, lung, 
breast
mir-34b, mir-34c Down, Hypermethylated
60% methylated in metastatic 
 primary tumors versus 40% meth-
ylated in non-metastatic  primary 
tumors
inhibition of cell 
migration
54
Prostate mir-34a Down, Hypermethylation 79.1%
increase in G1, 
 promotes apoptosis
55
Neuroblastoma mir-34a Down, Deletion of 1p36.23 ~30% Promotes apoptosis 56–58
epithelial Ovarian 
cancer
mir-34a, mir-34b, 
mir-34c
Down, Hypermethylation and 
copy number changes
mir-34a 100% and mir-34b/c 
72% in cases with p53 mutation. 
mir-34b/c reduced in advanced 
tumors
Decrease proliferation 
and invasion in cells 
with p53 mutation
59
Breast, lung mir-34b, mir-34c Deletion of 11q23-q24 ~48% Unknown 60
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This idea is particularly pertinent in the 
context of pancreatic ductal adenocar-
cinoma (PDAC). In a mouse model of 
PDAC an initial activating mutation in 
KRAS is followed by senescence, however 
a second mutation in p53 (creating mutant 
p53(R175H)) bypasses this growth arrest 
and such cells progress to PDAC.46 
Mutation of p53 (R175H) leads to the 
expression of a stable protein with domi-
nant-negative functions.47 Since miR-34c 
is a p53 target gene it is tempting to specu-
late that mutant p53 may inhibit miR-34c 
induction, leading to upregulation of Myc 
and bypass of senescence. Interestingly, 
unlike complete loss of p53, mutant p53 
(R175H) possess gain-of-function attri-
butes including promotion of invasion 
and metastases.48 Whilst hyper-methyl-
ation of the miR-34b/c promoter is well 
documented in metastatic cancer cells (see 
Table 1, and references therein), this dom-
inant negative function of mutant p53 in 
PDAC may be alternate mechanism to 
achieve suppression of miR-34b/c. Myc is 
known to be involved in metastasis49 and 
has recently been shown to activate miR-
9, a pro-metastatic microRNA,50 therefore 
it is possible that miR-34c acts upstream 
of miR-9 by repressing Myc. In this view 
miR-34c would lie at the centre of a tumor 
suppressor network to prevent oncogenic 
transformation and metastasis by repress-
ing Myc translation (Fig. 2).
Future Directions
Several crucial questions remain regard-
ing the regulation of Myc by miR-34c. 
Does miR-34c inhibit tumor metasta-
sis by repressing Myc? Does genetic loss 
of miR-34c in vivo lead to tumor for-
mation and is this dependent on Myc? 
Are there instances in human cancer in 
which this regulatory mechanism is lost, 
either through expression of mutant p53 
or through a single nucleotide polymor-
phism (SNP) in the Myc 3' UTR? What 
function does miR-34c play in the MK2 
DNA damage checkpoint? What tran-
scription factor activates miR-34c in the 
absence of p53? Is therapeutic manipula-
tion of miR-34c feasible? It is possible 
since therapeutic replacement of miR-34a 
in a mouse NSCLC xenograft model looks 
promising61 and miR-34c is a more potent 
for example, requires continued high lev-
els of Myc in order to bypass senescence 
and transform cells.45 Under conditions in 
which miR-34c induction is intact acti-
vation of the DDR by Ras would repress 
Myc and induce senescence, however loss 
of this regulatory mechanism could lead 
to a bypass of this growth arrest, contin-
ued proliferation and genomic instability. 
prevents continued DNA synthesis and 
proliferation in the presence of damaged 
DNA.11 These data have important impli-
cations, since activated oncogenes can 
promote genomic instability and engage 
a DNA damage response (DDR) leading 
to oncogene-induced senescence, a per-
manent growth arrest and innate tumor 
suppressor mechanism.44 Oncogenic Ras, 
Figure 1. Mir-34c is upregulated and Myc is repressed in response to sodium arsenite. HeK293 
cells were treated with 2.5 µM sodium arsenite for 8 hrs and levels of mir-34c and Myc deter-
mined by qPCr and western blot respectively.
Figure 2. the mir-34c-Myc pathway and downstream biological functions.
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anti-proliferative signal than miR34a.12 
Despite these many unanswered questions 
the available data clearly indicate a central 
role for miR-34c-dependent regulation of 
Myc in the prevention of human cancer 
initiation and progression.
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